Orphan Drugs
Lords · Question HL623 · Tabled 3 Jun 2026 · Department of Health and Social Care · Official record
Withdrawn
Question
Asked by Lord Kamall
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 11 March (HL15195), what assessment they have made of the suitability of conventional cost-effectiveness assessments for medicines where structural evidence constraints a